BDTX · Black Diamond Therapeutics, Inc. · Executive Compensation
$1.94
+0.05 (+2.65%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$107.44M
Shares
57.45M
Volume · Oct 5
839.14K
Avg daily vol (3M)
681.51K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Mark A. Velleca | M.D., Ph.D. President and Chief Executive Officer | $2,234,919 |
| Sergey Yurasov | M.D., Ph.D. Chief Medical Officer | $1,352,097 |
| Brent Hatzis-Schoch | Chief Operating Officer and General Counsel | $1,282,245 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Mark A. Velleca | M.D., Ph.D. President and Chief Executive Officer | $2,855,111 |
| Sergey Yurasov | M.D., Ph.D. Chief Medical Officer | $1,514,820 |
| Brent Hatzis-Schoch | Esq.(6) Chief Operating Officer and General Counsel | $1,405,116 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Mark A. Velleca | M.D., Ph.D. President and Chief Executive Officer | $2,949,854 |
| David M. Epstein | Ph.D. Former President and Chief Executive Officer | $2,019,206 |
| Fang Ni | Pharm.D. Chief Business Officer and Interim Chief Financial Officer | $1,489,526 |
| Sergey Yurasov | M.D., Ph.D. Chief Medical Officer | $1,233,684 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| David M. Epstein | Ph.D. Former President and Chief Executive Officer | $1,644,857 |
| Brent Hatzis-Schoch | Chief Operating Officer, General Counsel | $911,227 |
| Fang Ni | Pharm.D. Chief Business Officer and Interim Chief Financial Officer | $909,759 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| David M. Epstein | President and Chief Executive Officer | $5,090,225 |
| Brent Hatzis-Schoch | Chief Operating Officer, General Counsel | $2,022,309 |
| Fang Ni | Pharm.D. Chief Business Officer and Chief Financial Officer | $1,674,570 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| David M. Epstein | President and Chief Executive Officer | $3,868,216 |
| Rachel Humphrey | Chief Medical Officer | $2,979,288 |
| Brent Hatzis-Schoch | Chief Operating Officer, General Counsel | $1,527,044 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| David M. Epstein | President and Chief Executive Officer | $3,346,081 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Erika Jones | principal financial officer | Appointed | 2024-10-07 |
| Fang Ni | Chief Business Officer, Chief Financial Officer and principal financial officer | Terminated | 2024-10-07 |
| Shannon Campbell | Class III director | Appointed | 2024-04-11 |
| Prakash Raman, Ph.D. | Class I director | Appointed | 2024-04-11 |
| Wendy L. Dixon, Ph.D. | Board and all committees thereof, including her position as Chair of the Nominating and Corporate Governance Committee of the Bo | Resigned | 2024-04-11 |
| Alexander Mayweg, Ph.D. | Board of Directors | Resigned | 2024-04-11 |
| Rajeev Shah | member of the Company's Board of Directors | Resigned | 2024-01-18 |
| Mark Velleca, M.D., Ph.D. | Chief Executive Officer (CEO) | Appointed | 2023-09-18 |
| Mark A. Velleca | President and Chief Executive Officer and principal executive officer | Appointed | 2023-09-18 |
| David M. Epstein | President and Chief Executive Officer and principal executive officer | Terminated | 2023-09-18 |
| Mark A. Velleca, M.D., Ph.D. | Chairman of the Board | Appointed | 2022-12-19 |
| Robert A. Ingram | Chairman of the Board | Resigned | 2022-12-19 |